Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 July, 2017 00:22 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Moody's affirms ratings of seven and downgrades ratings of two Indian public sector banks - 24-Jul-2017 16:28
Moody's affirms ratings of Axis Bank, ICICI Bank; revises outlooks to stable - 24-Jul-2017 16:22
Ashok Leyland bags order worth Rs 6.50 bn - 24-Jul-2017 15:51
Lupin receives USFDA approval for Fluocinonide Topical Solution - 24-Jul-2017 15:29
Vijaya Bank Q1 net rises 58% - 24-Jul-2017 13:51
HDFC Bank Q1 net grows 20% to Rs 38.9 bn - 24-Jul-2017 13:36
MRSS acquires 100% stake in Market Probe Asia Pacific - 24-Jul-2017 12:28
Nucleus Software extends digitization capability of FinnOne Neo mCollect - 24-Jul-2017 11:08
Bank of Baroda enters into MoU with DGS&D - 24-Jul-2017 11:02
Zee Entertainment concludes acquisition of balance 49% stake in IWPL - 24-Jul-2017 10:27
Strides Shasun receives USFDA approval for Cetirizine Softgel Capsules - 24-Jul-2017 10:20
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer